JP2023545983A - リンパ系悪性腫瘍状態の二重特異性抗体治療 - Google Patents

リンパ系悪性腫瘍状態の二重特異性抗体治療 Download PDF

Info

Publication number
JP2023545983A
JP2023545983A JP2023520379A JP2023520379A JP2023545983A JP 2023545983 A JP2023545983 A JP 2023545983A JP 2023520379 A JP2023520379 A JP 2023520379A JP 2023520379 A JP2023520379 A JP 2023520379A JP 2023545983 A JP2023545983 A JP 2023545983A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
tpp
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023520379A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022076987A5 (https=
JP2023545983A5 (https=
Inventor
ハラランボス・ハドジバッシリオウ
タン・チュー
ジョンフン・スン
シャーミスタ・アチャラ
ジェフリー・ジョンソン
カンダサミ・ハリハラン
ホー・チョウ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2023545983A publication Critical patent/JP2023545983A/ja
Publication of JPWO2022076987A5 publication Critical patent/JPWO2022076987A5/ja
Publication of JP2023545983A5 publication Critical patent/JP2023545983A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023520379A 2020-10-07 2021-10-05 リンパ系悪性腫瘍状態の二重特異性抗体治療 Pending JP2023545983A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063088879P 2020-10-07 2020-10-07
US63/088,879 2020-10-07
PCT/US2021/071718 WO2022076987A1 (en) 2020-10-07 2021-10-05 Bispecific antibody treatment of lymphoid malignant neoplasm conditions

Publications (3)

Publication Number Publication Date
JP2023545983A true JP2023545983A (ja) 2023-11-01
JPWO2022076987A5 JPWO2022076987A5 (https=) 2024-10-10
JP2023545983A5 JP2023545983A5 (https=) 2024-10-10

Family

ID=78622127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023520379A Pending JP2023545983A (ja) 2020-10-07 2021-10-05 リンパ系悪性腫瘍状態の二重特異性抗体治療

Country Status (6)

Country Link
US (1) US20230365681A1 (https=)
EP (1) EP4225793A1 (https=)
JP (1) JP2023545983A (https=)
KR (1) KR20230083300A (https=)
CN (1) CN116685348A (https=)
WO (1) WO2022076987A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137576A1 (en) * 2023-12-22 2025-06-26 Nutcracker Therapeutics, Inc. Multiple specific antibodies targeting cd19, cd20, and/or cd47

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
JP2017525698A (ja) * 2014-08-15 2017-09-07 メルク パテント ゲーエムベーハー Ｓｉｒｐ−アルファ免疫グロブリン融合タンパク質
WO2019109876A1 (zh) * 2017-12-04 2019-06-13 北京韩美药品有限公司 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102338833B1 (ko) 2012-02-06 2021-12-13 인히브릭스, 인크. Cd47 항체 및 그 사용 방법
WO2016109415A1 (en) 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
CN109689684B (zh) 2016-07-06 2022-09-23 细胞基因公司 具有低免疫原性的抗体及其用途
BR112019020185A2 (pt) 2017-03-27 2020-06-02 Celgene Corporation Métodos e composições para redução da imunogenicidade
AU2019218271B2 (en) * 2018-02-12 2024-12-12 Forty Seven, LLC Anti-cancer regimen using anti-CD47 and anti-CD20 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514676A (ja) * 2013-03-15 2016-05-23 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 四価二重特異性抗体
JP2017525698A (ja) * 2014-08-15 2017-09-07 メルク パテント ゲーエムベーハー Ｓｉｒｐ−アルファ免疫グロブリン融合タンパク質
WO2019109876A1 (zh) * 2017-12-04 2019-06-13 北京韩美药品有限公司 抗pd‐l1/抗cd47天然抗体结构样异源二聚体形式双特异抗体及其制备

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 142, no. 5, JPN6025045450, 2010, pages 699 - 713, ISSN: 0005725394 *

Also Published As

Publication number Publication date
KR20230083300A (ko) 2023-06-09
US20230365681A1 (en) 2023-11-16
EP4225793A1 (en) 2023-08-16
WO2022076987A1 (en) 2022-04-14
CN116685348A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
JP2024074941A (ja) Ｃｄ４７の腫瘍選択的結合のための抗体の操作
CA3151307A1 (en) Anti-tigit antibodies and uses thereof
JP2023545983A (ja) リンパ系悪性腫瘍状態の二重特異性抗体治療
JP2025537137A (ja) 抗ｃｃｒ８抗体、化学療法及び免疫療法の組み合わせを使用する抗がん療法
JP2025508075A (ja) 抗ｉｌｔ２抗体及びその使用
WO2021245237A1 (en) Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
EP4681729A1 (en) Pharmaceutical composition containing pd-1/pvrig/tigit binding protein and medical use thereof
HK40087544A (zh) 改善与静脉内施用有关的抗体耐受性
HK40128286A (zh) 使用抗ccr8抗体、化学疗法和免疫疗法组合的抗癌疗法
HK40068966A (en) Engineering of an antibody for tumor-selective binding of cd47

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260203